Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

4.7K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
4.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CDK4/6 Inhibition Reverses MEIS2 Suppression of CRL4 <sup>CRBN</sup> to Enhance Immunomodulatory Drug Therapy in Multiple Myeloma.

bioRxiv : the preprint server for biology·2025
Same author

Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacy.

Frontiers in oncology·2025
Same author

Novel Strategies and Therapeutic Advances for Bladder Cancer.

Cancers·2025
Same author

Management of Patients with Muscle-Invasive Bladder Cancer Achieving A Clinical Complete Response after Neoadjuvant Therapy: Evidence and Consideration for Active Surveillance.

Current urology reports·2025
Same author

Single-Cell RNA Sequencing before and after Light Chain Escape Reveals Intrapatient Multiple Myeloma Subpopulations with Divergent Osteolytic Gene Expression.

Cancer research communications·2024
Same author

CD46-ADC Reduces the Engraftment of Multiple Myeloma Patient-Derived Xenografts.

Cancers·2023

Related Experiment Video

Updated: Apr 5, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K

Novel Induction Regimens in Multiple Myeloma.

Karie D Runcie1,2, Tomer M Mark3,4

  • 1Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medical College, New York, NY, USA. kdr9003@nyp.org.

Current Hematologic Malignancy Reports
|August 16, 2015
PubMed
Summary

Novel agents have improved multiple myeloma survival. This review critically analyzes combinations of these agents for newly diagnosed patients, focusing on transplant-eligible and ineligible individuals.

Keywords:
InductionMultiple myelomaNovel agentsTransplant eligibleTransplant ineligible

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.2K

Related Experiment Videos

Last Updated: Apr 5, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.2K

Area of Science:

  • Hematologic Malignancies
  • Oncology
  • Pharmacology

Background:

  • Multiple myeloma is a prevalent hematologic malignancy, primarily affecting older adults.
  • Recent advancements with novel agents (thalidomide, lenalidomide, bortezomib) have significantly enhanced patient outcomes.
  • Next-generation therapies like carfilzomib offer potential for deeper and longer remissions.

Purpose of the Study:

  • To critically analyze combination therapies involving novel agents for newly diagnosed multiple myeloma.
  • To evaluate treatment strategies for both transplant-eligible and transplant-ineligible patient groups.
  • To guide the selection of optimal therapy based on individual patient characteristics.

Main Methods:

  • Literature review focusing on clinical trials and studies of novel agents in multiple myeloma.
  • Comparative analysis of treatment regimens and their efficacy.
  • Assessment of treatment outcomes including progression-free survival and overall survival.

Main Results:

  • Novel agents have demonstrably improved survival and quality of life for multiple myeloma patients.
  • Combination therapies show promise for enhanced treatment efficacy.
  • Autologous stem cell transplant remains a key therapeutic option, though not universally applicable.

Conclusions:

  • The optimal selection of novel agent combinations is crucial for maximizing treatment benefits in newly diagnosed multiple myeloma.
  • Personalized therapeutic approaches are essential, considering patient eligibility for stem cell transplant.
  • Ongoing research into novel agent combinations will further refine treatment paradigms for multiple myeloma.